Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.

about

CT-perfusion measurements in pancreatic carcinoma with different kinetic models: Is there a chance for tumour grading based on functional parameters?Immunotherapy in pancreatic cancer treatment: a new frontier.

P2860

Q37508923-A376FF38-AEC9-4958-B350-21F896629049 Q39175499-F9DDACEA-6B41-4EFF-A3CB-50800AF666CC

P2860

Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.

Item

http://www.wikidata.org/entity/Q38221692

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.

@en

type

Item

label

Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.

@en

prefLabel

Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.

@en

P1476

Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.

@en

P2093

Meaghan L Khan

http://www.w3.org/2001/XMLSchema#string

Mitesh J Borad

http://www.w3.org/2001/XMLSchema#string

Thorvardur R Halfdanarson

http://www.w3.org/2001/XMLSchema#string

P2860

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

Vaccines for pancreatic cancer

Mucin-based targeted pancreatic cancer therapy

P304

1255-1275

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.13.277

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24947264

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

oncolytic virus

Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.

about

P2860

P2860

Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921